C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2026)

C4 Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $83.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 4.02% year-over-year to $83.5 million in Q1 2026; TTM through Mar 2026 was $314.9 million, a 18.57% decrease from a year earlier, with the FY2025 full-year figure at $101.0 million, up 9.94% from the prior year.
• Non-Current Assets retreated to $83.5 million in Q1 2026 per CCCC's latest filing, from $101.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $212.5 million in Q1 2022 and bottomed at $58.6 million in Q3 2025.
• The 5-year median for Non-Current Assets is $105.0 million (2024), against an average of $112.9 million.
• Across the five-year window, Non-Current Assets surged 308.76% in 2022 and tumbled 44.68% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $143.3 million in 2022, then fell by 26.54% to $105.3 million in 2023, then fell by 12.76% to $91.8 million in 2024, then grew by 9.94% to $101.0 million in 2025, then decreased by 17.31% to $83.5 million in 2026.
• Per Business Quant, the three latest CCCC Non-Current Assets figures stand at $83.5 million (Q1 2026), $101.0 million (Q4 2025), and $58.6 million (Q3 2025).